Werewolf Therapeutics, Inc. Common Stock
Here’s whether Werewolf Therapeutics, Inc. Common Stock (HOWL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-13.47% over 10 days); RSI 71 — overbought, elevated pullback risk; weak 1-year return of -68.8%; 3-month momentum negative (-47.5%). Currently 82.1% off its 52-week high. Score: -5/7.
HOWL is trading below its 200-day MA ($0.78) — a key warning sign the longer-term trend is under pressure. With an RSI of 70.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -68.8% compares to +16.5% for SPY (trailed the market by 85.3%). The current 82.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.